ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Supriya Lifescience earnings call we streamed: the live audio and our summary of what management said.
Q2 FY27 revenue ₹206 Cr (+3.2% YoY), EBITDA ₹45 Cr (-37.5%), margin 22%. LATAM regulatory shock, Ambernath ramp-up costs and raw material inflation hit margins; FY27 margin guidance cut to 23–25%.
Q2 FY27 revenue ₹206 Cr (+3.2% YoY), EBITDA ₹45 Cr (-37.5%), margin 22%. LATAM regulatory shock, Ambernath ramp-up costs and raw material inflation hit margins; FY27 margin guidance cut to 23–25%.
FY27 revenue target ₹1,000 Cr despite H1 ₹396 Cr; FY27 EBITDA margin 23–25%, no FY28 guidance.
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.
Supriya Lifescience achieved record Q4 revenue of ₹277cr, bringing FY26 revenue to ₹828cr. Management maintained its guidance of 20% annual growth and 33-35% EBITDA margins.
Supriya Lifescience delivered strong FY26 results with Q4 revenue surging 50% YoY, driven by the anesthetic segment and European market dominance.
Supriya Lifescience delivered strong performance in Q4FY26 with 50% YoY revenue growth, driven by expansion in Europe and new product launches in Cardiovascular and ADHD segments.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.